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ABSTRACT
Calcific uraemic arteriolopathy (CUA), or calciphylaxis, is a
rare disease predominantly occurring in comorbidity with dia-
lysis. Due to the very low frequency of CUA, prospective studies
on its management are lacking and even anecdotal reports on
treatment remain scarce. Therefore, calciphylaxis is still a
challenging disease with dismal prognosis urgently requiring
adequate strategies for diagnosis and treatment.
In an attempt to fill some of the current gaps in evidence
on various, highly debated and controversial aspects of
dialysis-associated calciphylaxis, 13 international experts joined
the 1st Consensus Conference on CUA, held in Leuven, Belgium
on 21 September 2015. The conference was supported by the
European Calciphylaxis Network (EuCalNet), which is a task
force of the ERA-EDTA scientific working group on Chronic
Kidney Disease—Mineral and Bone Disorders (CKD-MBD).
After an intense discussion, a 9-point Likert scale questionnaire
regarding 20 items on calciphylaxis was anonymously answered
by each participant. These 20 items addressed unsolved issues
in terms of diagnosis and management of calciphylaxis. On the
one hand, the analysis of the expert opinions identified areas of
general consensus, which might be a valuable aid for physicians
treating such a disease with less experience in the field. On the
other hand, some topics such as the pertinence of skin biopsy
and administration of certain treatments revealed divergent
opinions. The aim of the present summary report is to provide
some guidance for clinicians who face patients with calciphy-
laxis in the current setting of absence of evidence-based
medicine.
Keywords: calciphylaxis, cardiovascular, chronic renal failure,
CKD-MBD, mineral metabolism
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Calcific uraemic arteriolopathy (CUA), or calciphylaxis, is a rare
devastating syndrome (Orphanet number ORPHA280062)
characterized by progressive and painful skin ulcerations asso-
ciated withmedia calcification of small- andmedium-size vessels
in the dermis and subcutaneous tissue. It has an estimated inci-
dence of <1% among dialysis patients [1], who are the predom-
inantly affected patient cohort [2]. Currently, due to the paucity
of evidence from randomized controlled trials (RCTs), no stand-
ard treatment is available and patient management is primarily
based on physicians’ clinical experience and anecdotal reports.
As a consequence, calciphylaxis in patients on dialysis remains
a life-threatening condition with unmet clinical needs, urgently
requiring adequate diagnosis and treatment strategies.
Thirteen international experts in the field of calciphylaxis,
belonging to the areas of nephrology, cardiology and biochem-
istry and all listed as authors, joined the 1st Consensus Confer-
ence on CUA, held in Leuven, Belgium on 21 September 2015,
supported by the European Calciphylaxis Network (EuCalNet),
which is a Task Force of the European Renal Association—
European Dialysis and Transplant Association (ERA-EDTA)
scientific working group on Chronic Kidney Disease—Mineral
and Bone Disorders (CKD-MBD). Various issues were ad-
dressed, covering aspects related to dialysis-associated CUA
prevention, pathophysiology, diagnosis and treatment. Follow-
ing presentations by each expert on these particular topics of
expertise, an intensive discussion was started in an attempt to
reach a consensus on the standards for CUA diagnosis and
therapy. In order to evaluate each expert’s opinion, a 9-point
Likert scale questionnaire [3] (1, ‘strong disagreement’–9,
‘strong agreement’) was distributed at the end of the discussion
that comprised 20 items related to different aspects of calciphy-
laxis in dialysis patients. The items addressed were selected
based on their clinical relevance, but also on the group’s person-
al experience. Hence, not all of the aspects of potential interest
in the field were covered (e.g. hyperbaric oxygen therapy did
not turn out to be part of routine calciphylaxis treatment in
the involved centres). A score of 1–3 inferred ‘disagreement’,
4–6 ‘undecided/neutral’ and 7–9 ‘agreement’. Answers were an-
onymous and results were summarized graphically, with the
median score and the interquartile (Q1–Q3) range. L.J.S., as a
non-physician, did not participate in the vote.
In the following paragraphs, each item is reported along with
the corresponding graph and a brief comment including a
summary of the rationale justifying the experts’ answers.
ITEM 1
Performing a biopsy is a prerequisite for diagnosing CUA
(median 4.5; Q1–Q3 range 2–7)
The experts’ opinions vary from strong disagreement to
strong agreement (Figure 1A). The heterogeneous pattern of
the answers reflects the current debate on the role of skin biopsy
to confirm the diagnosis of calciphylaxis. Often the clinical pic-
ture is clear enough even without a biopsy, as the presence of
painful lesions and the association with advanced renal disease
and other possible risk factors raises a high suspicion of calci-
phylaxis. Dermal induration upon palpation (‘leather-like’) is
typical. Certainly skin biopsy is a useful tool in the workup of
the disease to exclude other conditions that can mimic it, and
thus to establish a definitive diagnosis [4, 5]. However, concerns
have been raised on the possibility that punch skin biopsy may
induce ulceration and worsen the disease course through super-
imposed infections, bleeding and induction of new areas of ne-
crosis [6]. Obviously, skin biopsy is a requirement for research
purposes. In summary, skin biopsy is not a prerequisite for es-
tablishing the diagnosis and should be limited to ambiguous
cases.
ITEM 2
The clinical picture is sufficient to diagnose CUA in most
cases (median 7; Q1–Q3 range 2–8)
The majority of experts [8/12 (67%)] agreed with this state-
ment, whereas others [4/12 (33%)] expressed disagreement
(Figure 1B). Indeed, although the degree of cutaneous and sub-
cutaneous tissue involvement is highly variable, superficial pain
is virtually always part of the initial clinical picture. Moreover,
the association with advanced renal disease as well as the palpa-
tion of firm calcified subcutaneous tissue is suggestive of the
diagnosis of calciphylaxis [4, 5].
ITEM 3
There are a high number of missed, undiagnosed cases
(median 8; Q1–Q3 range 6–9)
Most of the experts [9/12 (75%)] agreed that a potentially
high number of cases are missed (Figure 1C). This is due to
the fact that CUA is a rare disease and awareness might be sub-
optimal among caregivers [4, 5]. The exact number of hidden
cases, especially regarding minor or abortive forms, remains
speculative. The identification of minor or abortive stages of
calciphylaxis might be associated with improved outcome in
case therapy is started early rather than late after the develop-
ment of the full-blown clinical picture.
ITEM 4
CUA is a homogeneous disease irrespective of the nature
and the distribution of skin lesions (median 2.5; Q1–Q3
range 1.5–3)
The experts almost uniformly [10/12 (83%)] expressed dis-
agreement (Figure 1D), indicating a strong trend towards the
opinion that calciphylaxis is a heterogeneous disease. In fact,
the severe painful skin lesions at first presentationmay be of dif-
ferent types (i.e. livedo reticularis, reticulate purpura, violaceous
plaques or indurated nodules). Some patients with calciphylaxis
never develop ulcerations, while in others such ulcers dominate
the clinical picture from the early phases. The anatomical
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peripheral and a central form (abdominal and gluteal region)
[1, 4]. Overall, the experts consented that reliable diagnostic cri-
teria for calciphylaxis need to be established.
ITEM 5
Parathyroid hormone (PTH) levels within the Kidney
Disease: Improving Global Outcomes (KDIGO) target
range should be aimed for in dialysis calciphylaxis
patients (median 7; Q1–Q3 range 5–8)
The majority of experts agreed with this statement [7/12
(58%)], whereas the remainder [5/12 (42%)] were unsure (Fig-
ure 1E). However, in clinical practice, it is particularly difficult
to achieve an increase of low serum PTH levels (i.e. below the
KDIGO target range), which potentially reflect low-turnover
bone disease or adynamic bone disease (ABD) as one possible
trigger for CUA [2]. Conversely, it is relatively easy to bring ex-
cessively high PTH levels back to the KDIGO target range.
ITEM 6
In CUA patients on dialysis, PTH levels are
inappropriately low in terms of KDIGO target levels
(median 7; Q1–Q3 range 4–8)
Overall, the expert opinion is in agreement [10/12 (83%)]
with the statement that the levels of circulating PTH are in-
appropriately low (Figure 1F) compared with the PTH target
recommended by KDIGO [6], which suggests a target range
for PTH between two and nine times the upper limit of the nor-
mal reference range for the assay used (∼130–600 pg/mL).
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Indeed, data emerging from the German calciphylaxis registry
(2006–15) clearly showed that a high proportion of calciphy-
laxis patients on dialysis had PTH levels <130 pg/mL, indicative
of a low-turnover bone disease [2].
ITEM 7
A defect in calcification-inhibitory potency is a
prerequisite (median 6; Q1–Q3 range 3.5–8)
Although the answers distribute along the scale, the general
opinion is slightly shifted towards agreement, as 50% of experts
agreed with this item (Figure 2A) whereas the remaining 50%
expressed disagreement. This is due to the fact that available
data point towards the imbalance between calcification
promoters and inhibitors as a leading factor in extraosseous
calcification in CKD rather than just inhibitors. Indeed, preclin-
ical and clinical studies have shown the involvement of a pleth-
ora of factors, both systemic circulating and local, that may act
differently on different parts of the arterial tree in the dev-
elopment of unwanted calcification processes in the body [7].
Notably, the discovery of these mechanisms has led to the de-
velopment of specific interventions aimed at promoting a new
balance between pro- and anti-calcifying factors [1]. Among in-
hibitors, the current focus is on matrix Gla protein (MGP), a
protein exclusively expressed in vascular smooth muscle cells
and chondrocytes. To be fully active, MGP requires post-
translational phosphorylation and vitamin K–dependent
gamma-carboxylation; accordingly, warfarin treatment sup-
presses MGP activation [8].
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Vitamin K antagonist intake is a risk factor for CUA
(median 8.5; Q1–Q3 range 7.5–9)
The experts fully (100%) agreed that the use of vitamin K an-
tagonists (VKAs) increases the risk of CUA (Figure 2B). Al-
though clear evidence from prospective clinical trials is
lacking, in vitro, in vivo and human cohort studies have
shown that the use of VKAs such as warfarin accelerates cardio-
vascular calcification [8–10] and increases the risk of calciphy-
laxis [11, 12]. Biochemically, one possible explanation resides in
the key role of vitamin K–dependent post-translational modifi-
cations required for the activation of the calcification inhibitor
MGP (see Item 5). A recent report from Delanaye et al. [13]
showed that stopping VKA in seven haemodialysis (HD)
patients led to a rapid and significant reduction of inactive
MGP levels, although no data are available yet on the effect of
this reduction on vascular calcification or on calciphylaxis
outcomes.
ITEM 9
In CUA patients on dialysis the calcium × phosphorus
(Ca × P) product is markedly elevated (median 3.5; Q1–Q3
range 2.5–5.5)
Although the experts’ answers are spread along the scale, the
overall opinion is slightly shifted towards disagreement [6/12
(50%)] (Figure 2C). The rationale behind this answer is that
an increased level of circulating Ca × P product has been
shown to be a predictor of cardiovascular risk and calcification
in the majority of dialysis patients, and a risk factor for calci-
phylaxis [14, 15]. On the other hand, various reports have de-
monstrated that many cases have occurred in the presence of
apparently low or normal serum Ca levels [2]. In fact, a normal
Ca × P product may result from an impaired capacity of serum
to keep Ca and P ions in solution, leading to a rapid deposition
of Ca and P within extraosseous calcifications [16]. Overall, the
experts agreed that overt (constant) hypercalcaemia is not a
prerequisite for calciphylaxis. Previous data from the German
calciphylaxis registry indicated that CKD-MBD parameters
are highly variable in calciphylaxis patients [2].
ITEM 10
Besides the uraemic state, CUA is triggered by as yet to be
defined iatrogenic factors (median 7; Q1–Q3 range 3–8)
The majority of experts [7/12 (67%)] agreed with this item,
whereas the remainder equally expressed uncertainty [2/12
(17%)] or disagreement [2/12 (17%)] (Figure 2D). Indeed,
in contrast to hypertension or anaemia, calciphylaxis is not
an issue of previously unrecognized or neglected CKD. Virtu-
ally all patients with CUA have been regularly monitored for a
long period of time and develop CUA despite intensive
surveillance.
ITEM 11
Diabetes is a risk factor for CUA in dialysis patients
(median 7; Q1–Q3 range 5.5–8.5)
The majority of experts [8/12 (67%)] agreed with this
item, whereas the remainder [4/12 (33%)] were undecided
(Figure 2E). The rationale behind this result resides in the
observation that diabetes is a frequent comorbidity in CUA
patients and it is not a condition sine qua non. Moreover, the
association between calciphylaxis and diabetes, just like all
the other risk factors, has not been rigorously studied to con-
firm causality, and data come from studies suffering from
limitations such as small sample size and single-centre ex-
perience [1, 17]. Finally, no data are available regarding
whether diabetes control or duration affects calciphylaxis
risk [17].
ITEM 12
CUA treatment should be multimodal (median 9; Q1–Q3
range 7.5–9)
The experts unanimously agreed with the statement that
treatment of CUA should be multimodal (Figure 3A). Such
a multimodal approach has been previously recommended
[1, 17]. Multimodality has been reported to be associated
with successful CUA resolution [5, 17, 18], although patients
should be carefully evaluated on a case-by-case basis. Overall,
the discovery of a single magic bullet for CUA treatment is
unlikely.
ITEM 13
Increasing dialysis intensity [duration, frequency, switch
from peritoneal dialysis (PD) to HD, etc.] should be
considered (median 7; Q1–Q3 range 5–8.5)
Most of the experts [8/12 (67%)] agreed with the state-
ment that intensifying dialysis should be taken into consid-
eration, whereas the remainder [4/12 (33%)] were unsure
(Figure 3B). In general, due to the lack of clear evidence on
any of the proposed interventions to better control CUA,
treatment recommendations are largely based on clinical ex-
perience and results from observational studies. The aim of
dialysis intensification, possibly through increased length
and frequency, or switching from HD to hemodiafiltration
(HDF) or from PD to HD or HDF, is to enhance calcium
and phosphate removal. Notably, intensifying HD has been
recommended by Baldwin et al. [18], whereas concerns have
been raised on the use of PD, as it may confer higher calci-
phylaxis risk. The reason for the increased CUA incidence
among PD patients remains unclear, but one possibility is
the use of calcium-containing phosphate binders. The switch
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Reducing calcium intake and supply should be considered
(median 7; Q1–Q3 range 5.5–8)
The overall opinion is of agreement [8/12 (67%)] with this
item (Figure 3C). It is well established that, together with
phosphate, calcium is the main component of vascular calcifi-
cations. However, relatively normal or even low serum calcium
levels are possible at the time of calciphylaxis diagnosis, due to
its tissue deposition. Fine and Fontaine [19] reported that after
reducing the amount of calcium salts given to dialysis patients
(mostly PD), the incidence of CUA significantly decreased over
several years in their dialysis centre.
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Stopping vitamin K antagonist treatment should be
considered (median 8; Q1–Q3 range 7–9)
The experts expressed complete agreement with this state-
ment (Figure 3D). Indeed, compelling evidence has shown
that VKA treatment is a risk factor for calciphylaxis (see Item
7) [2]. Ongoing VKA prescription should be limited to very few
CUA cases, such as patients with mitral prosthetic heart valve
replacement.
ITEM 16
Vitamin K supplementation should be considered
(median 7; Q1–Q3 range 5–8)
The majority of experts [7/12 (58%)] agreed with this item,
whereas the remainder were unsure [5/12 (42%)] (Figure 3E).
As already stated lessons learned from in vitro and in vivo stud-
ies highlight the key role of vitamin K in protecting from and
possibly reverting vascular calcifications [8, 10, 20]. Moreover,
it has been recently demonstrated that most dialysis patients ex-
hibit pronounced vitamin K deficiency and that supplementa-
tion with vitamin K2 in HD patients can markedly decrease the
levels of inactive MGP in a dose-dependent fashion [21, 22].
However, more data from RCTs are needed to understand
whether supplementation of vitamin K may be of benefit for
the cardiovascular health of patients [23]. According to the ex-
pert discussion, it seems that there is no clear rationale for pre-
ferring K2 (menaquinone-7) over K1 supplementation.
Vitamin K application in CKD patients was regarded as being
generally safe by the experts.
ITEM 17
Sodium thiosulfate is a first-line treatment option
(median 6; Q1–Q3 range 4–8)
The experts expressed heterogeneous opinions with regard
to this item, as 58% (7/12) were uncertain, 33% (4/12) agreed
and 1 expert disagreed (Figure 3F). Sodium thiosulfate (STS)
has been available as a chelating agent indicated for the treat-
ment of cyanide intoxication; as an off-label indication, how-
ever, it is a common intervention used to treat calciphylaxis.
STS has been used in calciphylaxis patients, often as part of a
multimodal approach, resulting in clinical improvements
[24–26] including a reduction in pain. Yet, a definitive con-
clusion on the efficacy and safety of STS cannot be drawn,
since prospective controlled data are missing. Moreover, a
publication bias favouring positive results cannot be ex-
cluded. Concerns exist about the duration of therapy with
STS, the dose, the method of administration and the cost,
which may affect the choice and duration of this drug as a
feasible option for these patients [1]. Potential side effects
such as induction of metabolic acidosis and bone demineral-
ization warrant attention.
ITEM 18
Bisphosphonates are afirst-line treatment option (median
2.5; Q1–Q3 range 2–5)
Most of the experts expressed disagreement [8/12 (67%)]
with this item, whereas 1 expert agreed and the remaining 3
were undecided (Figure 3G). It is unclear whether they inter-
act with extraosseous calcification processes via their antire-
sorptive bone effects or via direct peripheral pyrophosphate-
like effects at the tissue sites. Published data are scarce, and
mostly from case reports and case series [27, 28], and there-
fore the routine use of this molecules is not indicated. More-
over, as they may worsen ABD, especially in patients with
stage 4–5D CKD, their use should be considered only in se-
lected cases in which ABD is excluded or highly unlikely.
ITEM 19
Parathyroidectomy or cinacalcet are major treatment
options in CUA (median 4.5; Q1–Q3 range 3.5–7)
The experts’ opinions are dispersed between disagreement
and agreement, but 42% (5/12) expressed uncertainty (Fig-
ure 3H). The choice of parathyroidectomy or cinacalcet strong-
ly depends on the patient’s characteristics and therefore their
use must be carefully evaluated for each individual patient. In
calciphylaxis patients with overt hyperparathyroidism and
signs of high bone turnover, ‘emergency’ parathyroidectomy
should be considered. The EVOLVE trial (n = 3861 dialysis pa-
tients) investigated the occurrence of calciphylaxis with respect
to cinacalcet compared with placebo treatment [29]. Of note, in
EVOLVE the median PTH levels prior to CUA development
were 796 pg/mL in the placebo arm (n = 18 cases) and 410
pg/mL in the cinacalcet arm (n = 6 cases) [29]. The unadjusted
relative hazard was 0.31 (95% CI 0.13–0.79; P = 0.014). Import-
antly, the EVOLVE study included preselected dialysis patients
with advanced hyperparathyroidism at baseline, while a nation-
wide approach such as the German registry [2] is unlimited by
any exclusion criteria. So the EVOLVE cohort is presumably
not representative regarding the predominant PTH range for
calciphylaxis development and at the same time fuels specula-
tion about an optimal intermediate (protective) PTH range.
ITEM 20
Prognosis of CUA is poor (median 8.5; Q1–Q3 range
7.5–9)
The experts evenly agreed that, to date, CUA prognosis re-
mains dismal (Figure 4). In fact, it is associated with high mor-
bidity, mostly depending on infections and cardiovascular
disorders, and a mortality of up to 80%, likely due to infections
of necrotic skin resulting in sepsis [30]. Lessons from clinical
experience have shown that patients with large ulcerative skin
lesions carry the worst prognosis, particularly based on the in-
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What emerges from the experts’ answers is that a general con-
sensus actually exists on specific issues related to calciphylaxis
diagnosis, risk factors and treatment strategies, although based
mainly on daily practice experience and observational studies
rather than on clear evidence from RCTs. Nevertheless, the pre-
sent article cannot cover all aspects of calciphylaxis and the ex-
perts acknowledge the presence of some topics that remain the
objective of an open debate, such as whether it is appropriate to
perform skin biopsy at the time of diagnosis or to administer
certain treatments to dialysis patients with calciphylaxis (e.g.
hyperbaric oxygen therapy or statins), therefore highlighting
major targets for future research efforts.
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